Albasvir

Albasvir is a direct‑acting antiviral medication used in combination with grazoprevir for the treatment of chronic hepatitis C virus (HCV) infection. As a potent NS5A inhibitor, Albasvir disrupts viral replication and assembly by targeting a protein essential for the HCV life cycle. Albasvir is supplied as a crystalline solid with a purity of ≥98% (HPLC). The macrocyclic structure of Albasvir is characterized by multiple stereocenters that confer high affinity and selectivity for NS5A. Albasvir is also available as a reference standard for analytical method development, method validation, and quality control applications in ANDA filings.Albasvir is a direct‑acting antiviral medication used in combination with grazoprevir for the treatment of chronic hepatitis C virus (HCV) infection. As a potent NS5A inhibitor, Albasvir disrupts viral replication and assembly by targeting a protein essential for the HCV life cycle. Albasvir is supplied as a crystalline solid with a purity of ≥98% (HPLC). The macrocyclic structure of Albasvir is characterized by multiple stereocenters that confer high affinity and selectivity for NS5A. Albasvir is also available as a reference standard for analytical method development, method validation, and quality control applications in ANDA filings.

 

Product Parameters

---

Parameter	Specification
Product Name	Albasvir (Elbasvir)
CAS Number	1370468-36-2
Molecular Formula	C₄₉H₅₅N₉O₇
Molecular Weight	882.02 g/mol
Density	1.40±0.1 g/cm3
Storage Condition	2-8 ℃
pKa	11.22±0.46
Physical Form	Crystalline solid

 

Medications for chronic hepatitis Cinfection

---

Elbaviride tablets are a cutting-edge direct-acting antiviral drug indicated for the treatment of hepatitis C virus types 1 and 4. Currently, there are approximately 10 million hepatitis C virus carriers in China, among whom over 50% are infected with hepatitis C virus genotype 1b. Merck & Co. advocates for an individualized approach to hepatitis C treatment, encouraging physicians and patients to select appropriate therapeutic regimens based on factors such as hepatitis C virus genotyping, the patient's clinical condition, medication history, and economic status. This strategy aims to enhance treatment accessibility, reduce overall treatment costs, and provide patients with advanced yet affordable treatment options.

 

In 2019, Merck & Co. had four drugs included in the National Reimbursement Drug List (NRDL), namely Elbavir pegylate and ribavirin tablets,(Nocovax®), levosuguanide tablets (Angio®), and sitagliptin and metformin tablets (Jenotada®), covering four major therapeutic areas: hepatitis C, fungal infections, pulmonary hypertension, and diabetes. Additionally, the targeted drug for ovarian cancer developed and promoted jointly by Merck & Co. and AstraZeneca was also included in the NRDL for that year.

 

 Why Cosperpharm?

---

When your HCV antiviral development program or ANDA filing for elbasvir requires reliable APIs and reference standards, Cosperpharm delivers Albasvir with the analytical rigor, documentation depth, and supply flexibility that pharmaceutical customers demand.

 

Antiviral potency begins with stereochemical purity. The complex macrocyclic structure of Albasvir contains multiple chiral centers that are critical for its high‑affinity binding to NS5A. Any stereochemical impurity in this API will compromise antiviral activity and increase the risk of resistance. Our analytical release protocol for Albasvir includes HPLC purity verification (≥98%), chiral purity assessment by chiral HPLC, residual solvent analysis, and identity confirmation by NMR and MS — because your final drug product's antiviral efficacy depends on the quality of this API.

 

Documentation that supports regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch‑specific HPLC purity, chromatographic traceability, and residual solvent data — structured for direct insertion into your method validation package. DMF‑ready documentation, stability summaries, and custom quality agreements are available upon request.

 

Flexible supply across all development stages. Cosperpharm supplies Albasvir across the full range of applications — from 1g–50g reference standard quantities for QC impurity profiling and analytical method development, to 100g–500g batches for process validation and pilot production. R&D samples ship within 5–7 business days; bulk orders ship within 2–3 weeks.

 

Technical support for the full synthetic cascade. Our process chemistry team can advise on the macrocyclization conditions, purification strategies for stereoisomer removal, and analytical methods for detecting process‑related impurities — because we have worked extensively with this NS5A inhibitor scaffold across multiple manufacturing campaigns.

 

Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and analytical laboratories worldwide, with full customs documentation included. Volume discounts apply, and we communicate lead times upfront — no hidden fees, no unexpected delays.

 

FAQ

---

Q1: What is Albasvir used for?

A: Albasvir (elbasvir) is a direct‑acting antiviral medication indicated for the treatment of chronic hepatitis C virus (HCV) infection, used in combination with grazoprevir.

 

Q2: What is the mechanism of action of Albasvir?

A: Albasvir inhibits the HCV non‑structural protein 5A (NS5A), which is essential for viral RNA synthesis and virion assembly.

 

Contact Us

---

Looking for high‑quality Albasvir for your HCV antiviral manufacturing or analytical development program? Cosperpharm is here to help. Contact our team today for pricing, documentation, or technical support — we are committed to delivering the quality and service you need.